Phaseline

Companies › Virogin Biotech

Virogin Biotech: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VG2025
Recombinant human IL-12/IL-15 dual-regulated oncolytic HSV-1
–Phase 2Intrahepatic Cholangiocarcinoma; Advanced Malignant Solid TumorJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07522476VG2025Phase 2Intrahepatic CholangiocarcinomaOncologyJan 2028
NCT07682870VG2025Phase 1Advanced Malignant Solid TumorOncologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.